View Item 

Show simple item record

Analysis Approaches to Identify Pharmacogenetic Associations With Pharmacodynamics

dc.contributor.authorHertz, Daniel L.
dc.contributor.authorRamsey, Laura B.
dc.contributor.authorGopalakrishnan, Mathangi
dc.contributor.authorLeeder, J. Steven
dc.contributor.authorVan Driest, Sara L.
dc.date.accessioned2021-09-08T14:36:05Z
dc.date.available2022-10-08 10:36:04en
dc.date.available2021-09-08T14:36:05Z
dc.date.issued2021-09
dc.identifier.citationHertz, Daniel L.; Ramsey, Laura B.; Gopalakrishnan, Mathangi; Leeder, J. Steven; Van Driest, Sara L. (2021). "Analysis Approaches to Identify Pharmacogenetic Associations With Pharmacodynamics." Clinical Pharmacology & Therapeutics (3): 589-594.
dc.identifier.issn0009-9236
dc.identifier.issn1532-6535
dc.identifier.urihttps://hdl.handle.net/2027.42/169303
dc.publisherWiley Periodicals, Inc.
dc.titleAnalysis Approaches to Identify Pharmacogenetic Associations With Pharmacodynamics
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelPharmacy and Pharmacology
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/169303/1/cpt2312_am.pdf
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/169303/2/cpt2312.pdf
dc.identifier.doi10.1002/cpt.2312
dc.identifier.sourceClinical Pharmacology & Therapeutics
dc.identifier.citedreferenceHertz, D.L. et al. Paclitaxel plasma concentration after the first infusion predicts treatment‐limiting peripheral neuropathy. Clin. Cancer Res. 24, 3602 – 3610 ( 2018 ).
dc.identifier.citedreferenceGonsalves, S.G. et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes. Clin. Pharmacol. Ther. 105, 1338 – 1344 ( 2019 ).
dc.identifier.citedreferenceMcLaughlin, M.J., Wagner, J., Shakhnovich, V., Carleton, B. & Leeder, J.S. Considerations for implementing precision therapeutics for children. Clin. Transl. Sci. 12, 140 – 150 ( 2019 ).
dc.identifier.citedreferenceTavira, B. et al. KCNQ1 gene variants and risk of new‐onset diabetes in tacrolimus‐treated renal‐transplanted patients. Clin. Transplant. 25, E284 – E291 ( 2011 ).
dc.identifier.citedreferenceOetting, W.S. et al. Genetic variants associated with immunosuppressant pharmacokinetics and adverse effects in the DeKAF genomics genome‐wide association studies. Transplantation 103, 1131 – 1139 ( 2019 ).
dc.identifier.citedreferenceBrown, J.T., Abdel‐Rahman, S.M., van Haandel, L., Gaedigk, A., Lin, Y.S. & Leeder, J.S. Single dose, CYP2D6 genotype‐stratified pharmacokinetic study of atomoxetine in children with ADHD. Clin. Pharmacol. Ther. 99, 642 – 650 ( 2016 ).
dc.identifier.citedreferenceBrown, J.T. et al. Clinical pharmacogenetics implementation consortium guideline for Cytochrome P450 (CYP)2D6 genotype and atomoxetine therapy. Clin. Pharmacol. Ther. 106, 94 – 102 ( 2019 ).
dc.identifier.citedreferencePeck, C. The randomized concentration‐controlled clinical trial (CCR): an information rich alternative to the randomized placebo controlled clinical trial (PCT). Clin. Pharmacol. Ther. 47, 148 ( 1990 ).
dc.identifier.citedreferenceGaedigk, A., Dinh, J.C., Jeong, H., Prasad, B. & Leeder, J.S. Ten years’ experience with the CYP2D6 activity score: a perspective on future investigations to improve clinical predictions for precision therapeutics. J. Pers. Med. 8, 15 ( 2018 ).
dc.identifier.citedreferenceVan Driest, S.L. et al. Genome‐wide association study of serum creatinine levels during vancomycin therapy. PLoS One 10, e0127791 ( 2015 ).
dc.identifier.citedreferenceTomita, T. et al. The influence of 5‐HTTLPR genotype on the association between the plasma concentration and therapeutic effect of paroxetine in patients with major depressive disorder. PLoS One 9, e98099 ( 2014 ).
dc.identifier.citedreferenceBoswell, M.V. et al. The role of hydromorphone and OPRM1 in postoperative pain relief with hydrocodone. Pain Physician. 16, E227 – E235 ( 2013 ).
dc.identifier.citedreferenceMarcath, L.A. et al. Genetic variation in EPHA contributes to sensitivity to paclitaxel‐induced peripheral neuropathy. Br. J. Clin. Pharmacol. 86, 880 – 890 ( 2020 ).
dc.identifier.citedreferenceUpton, R.N. & Mould, D.R. Basic concepts in population modeling, simulation, and model‐based drug development: part 3‐introduction to pharmacodynamic modeling methods. CPT Pharmacometrics Syst. Pharmacol. 3, e88 ( 2014 ).
dc.identifier.citedreferenceNgaimisi, E., Gopalakrishnan, M., Ivaturi, V., Zhang, W., Young, M. & Laffont, C.M. Exposure‐response analyses to support dosing recommendations for RBP‐6000 buprenorphine monthly formulation in subjects with opioid use disorder. J. Pharmacokinet. Pharmacodyn. 44, S50 ( 2017 ).
dc.identifier.citedreferenceKuepfer, L. et al. Applied concepts in PBPK modeling: how to build a PBPK/PD model. CPT Pharmacometrics Syst. Pharmacol. 5, 516 – 531 ( 2016 ).
dc.identifier.citedreferenceVan Driest, S.L. et al. Pragmatic pharmacology: population pharmacokinetic analysis of fentanyl using remnant samples from children after cardiac surgery. Br. J. Clin. Pharmacol. 81, 1165 – 1174 ( 2016 ).
dc.identifier.citedreferenceDiouf, B. & Evans, W.E. Pharmacogenomics of vincristine‐induced peripheral neuropathy: progress continues. Clin. Pharmacol. Ther. 105, 315 – 317 ( 2019 ).
dc.identifier.citedreferenceSharma, M.R. et al. A UGT1A1 genotype‐guided dosing study of modified FOLFIRINOX in previously untreated patients with advanced gastrointestinal malignancies. Cancer 125, 1629 – 1636 ( 2019 ).
dc.identifier.citedreferenceLeeder, J.S. Who believes they are "just average": informing the treatment of individual patients using population data. Clin. Pharmacol. Ther. 106, 939 – 941 ( 2019 ).
dc.identifier.citedreferenceCaudle, K.E. et al. Standardizing CYP2D6 genotype to phenotype translation: consensus recommendations from the clinical pharmacogenetics implementation consortium and Dutch Pharmacogenetics Working Group. Clin. Transl. Sci. 13, 116 – 124 ( 2020 ).
dc.identifier.citedreferenceBirdwell, K.A. et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for CYP3A5 genotype and tacrolimus dosing. Clin. Pharmacol. Ther. 98, 19 – 24 ( 2015 ).
dc.identifier.citedreferenceCrews, K.R. et al. Clinical pharmacogenetics implementation consortium guideline for CYP2D6, OPRM1, and COMT genotypes and select opioid therapy. Clin. Pharmacol. Ther. ( 2021 ). https://doi.org/10.1002/cpt.2149. [e‐pub ahead of print].
dc.identifier.citedreferenceHertz, D.L. & McLeod, H.L. Using pharmacogene polymorphism panels to detect germline pharmacodynamic markers in oncology. Clin. Cancer Res. 20, 2530 – 2540 ( 2014 ).
dc.identifier.citedreferenceDaly, A.K. Using genome‐wide association studies to identify genes important in serious adverse drug reactions. Annu. Rev. Pharmacol. Toxicol. 52, 21 – 35 ( 2012 ).
dc.working.doiNOen
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
cpt2312_am.pdf
Size:
273.8KB
Format:
PDF
View/Open
Name:
cpt2312.pdf
Size:
489.1KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.